Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECAP: Regorafenib and Capecitabine in Locally Advanced Rectal Cancer
NCT02910843Phase 1Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Feb 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regorafenib in rectal cancer, sponsored by Swiss Group for Clinical Cancer Research. Primary endpoints: Dose limiting toxicity and Pathological near complete or complete tumor response. Started Feb 2017; status: terminated.
02
Drugs
regorafenib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02910843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910843.